The Role of Adaptive Radiotherapy in Definitive Radiation of Nasopharyngeal Cancer: A Review of Dosimetry

被引:0
|
作者
Barata, Andreas Ronald [1 ]
Sekarutami, Sri Mutya [1 ]
Kodrat, Henry [1 ]
Handoko [1 ]
Nasution, Nuruddin [2 ]
Hudiya, Elian [1 ]
机构
[1] Univ Indonesia, Cipto Mangunkusumo Gen Hosp, Dept Radiat Oncol, Fac Med, Jakarta, Indonesia
[2] Univ Indonesia, Cipto Mangunkusumo Gen Hosp, Dept Med Phys, Fac Med, Jakarta, Indonesia
来源
关键词
Nasopharyngeal cancer; radiation dosimetry; radiotherapy; INTENSITY-MODULATED RADIOTHERAPY; WEIGHT-LOSS; CARCINOMA; HEAD; IMPACT;
D O I
10.5505/tjo.2023.3938
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
OBJECTIVEThis study aimed to evaluate the dosimetry changes and provide an overview of the time for radiation planning adjustments.METHODSThis prospective cohort study recruited nasopharyngeal cancer patients aged 18 or older. Radiation planning adjustment was performed if at least one normal organ at-risk or target volume deviated from the criteria.RESULTSA total of 11 patients were included as study subjects. After completing up to the 30th fraction of radiation, 8 of 11 patients lost more than 10% of their weight and required adjustments in their radiation plan. The analysis of the relationship between the fractionation time and planning adjustment showed the greatest increase in fractions 11 to 16, RR: 2.83 (1.74-4.61) and 4.76 (2.35-9.65), with a statistically significant result (p=0.000). The widest neck separation demonstrated the highest sensitivity of plan adjustment need (93.3%) and specificity (87.5%) at 1.21 cm with an area under the curve (AUC) of 0.951 and a 95% CI of 0.905-0.996 (p<0.001). The mastoid tip separation showed the highest plan adjustment need sensitivity of 93.3% and specificity of 40.6% at 0.435 cm with an AUC of 0.741, 95% CI 0.631-0.852 (p<0.001). The Delta body weight percentage showed the plan adjustment needs a sensitivity of 91.1% and specificity of 81.2% at 4.49 with an AUC of 0.911, 95% CI 0.844-0978 (p<0.001).CONCLUSIONThe radiation planning adjustment in patients with locally advanced nasopharyngeal cancer is suggested at the 16th fraction, the 3rd week. It is recommended at the widest lymph node area separation of 1.21 cm or a weight loss percentage of 4.49%.
引用
收藏
页码:373 / 381
页数:9
相关论文
共 50 条
  • [1] Definitive radiotherapy for nasopharyngeal carcinoma
    Mendenhall, William M.
    Morris, Christopher G.
    Hinerman, Russell W.
    Malyapa, Robert S.
    Amdur, Robert J.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (06): : 622 - 627
  • [2] RADIATION-INDUCED MALIGNANCY FOLLOWING DEFINITIVE RADIOTHERAPY FOR NASOPHARYNGEAL CARCINOMA
    Xi, M.
    Zhang, L.
    Liu, M.
    Li, Q.
    ANNALS OF ONCOLOGY, 2012, 23 : 343 - 343
  • [3] Definitive radiotherapy for juvenile nasopharyngeal angiofibroma
    McAfee, WJ
    Morris, CG
    Amdur, RJ
    Werning, JW
    Mendenhall, WM
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (02): : 168 - 170
  • [4] An in-vivo dosimetry clinical decision model for adaptive radiotherapy of nasopharyngeal carcinoma
    Yang, Long
    Li, Zhenhao
    Wang, Jiazhou
    Hu, Weigang
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S4043 - S4044
  • [5] Which nasopharyngeal cancer patients need adaptive radiotherapy?
    Yu-Chang Hu
    Kuo-Wang Tsai
    Ching-Chih Lee
    Nan-Jing Peng
    Ju-Chun Chien
    Hsin-Hui Tseng
    Po-Chun Chen
    Jin-Ching Lin
    Wen-Shan Liu
    BMC Cancer, 18
  • [6] Which nasopharyngeal cancer patients need adaptive radiotherapy?
    Hu, Yu-Chang
    Tsai, Kuo-Wang
    Lee, Ching-Chih
    Peng, Nan-Jing
    Chien, Ju-Chun
    Tseng, Hsin-Hui
    Chen, Po-Chun
    Lin, Jin-Ching
    Liu, Wen-Shan
    BMC CANCER, 2018, 18
  • [7] PLASMA EBV DNA IN NASOPHARYNGEAL CANCER (NPC) TREATED WITH DEFINITIVE RADIOTHERAPY (RT)
    Stutheit-Zhao, Eric
    King, Ian
    Huang, Shao Hui
    Rey-McIntyre, Katrina
    Cho, John
    Eng, Lawson
    Hahn, Ezra
    Hosni, Ali Abdalaty
    Kim, John
    Tadic, Tony
    McNiven, Andrea
    McPartlin, Andrew
    Ringash, Jolie
    O'Sullivan, Brian
    Siu, Lillian
    Spreafico, Anna
    Tsai, C. Jillian
    Waldron, John N.
    Hope, Andrew
    Bratman, Scott V.
    RADIOTHERAPY AND ONCOLOGY, 2023, 186 : S4 - S5
  • [8] Plasma EBV DNA in Nasopharyngeal Cancer (NPC) Treated with Definitive Radiotherapy (RT)
    Stutheit-Zhao, E.
    King, I.
    Huang, S. H.
    Rey-McIntyre, K.
    Cho, J.
    Eng, L.
    Hahn, E.
    Hosni, A.
    Kim, J.
    Tadic, T.
    McNiven, A. L.
    McPartlin, A.
    Ringash, J. G.
    O'Sullivan, B.
    Siu, L. L.
    Spreafico, A.
    Tsai, C. J.
    Waldron, J.
    Hope, A. J.
    Bratman, S. V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E627 - E628
  • [9] Addition of Definitive Radiotherapy to Chemotherapy in Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer
    Verma, Vivek
    Allen, Pamela K.
    Simone, Charles B., II
    Gay, Hiram A.
    Lin, Steven H.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (11): : 1383 - 1391
  • [10] Reconsidering the Role of Radiotherapy for Inoperable Gastric Cancer: A Systematic Review of Gastric Radiotherapy Given With Definitive and Palliative Intent
    Case, A.
    Williams, F.
    Prosser, S.
    Hutchings, H.
    Crosby, T.
    Adams, R.
    Jenkins, G.
    Gwynne, S.
    CLINICAL ONCOLOGY, 2025, 37